Rivermark pockets $20m in Series D for late-stage prostate device trial

The raise will support Rivermark’s pivotal trial, while allowing the medtech company to ready its FloStent system for ...
MassDevice

Rivermark Medical brings in $20M to support FloStent device for BPH

Andera Partners said today that it led a $20 million Series D financing round for urology-focused medical device maker ...
FierceBiotech

FDA greenlights Urotronic's drug-coated balloon for BPH

The FDA has expanded the use of a drug-coated balloon developed by Urotronic for male urinary procedures, which the company describes as one of the first of a new generation of devices in the space.
Berkshire Eagle

FDA Approves the ProVee System - the First of a New Generation of Prostatic Urethral Stents for Treatment of BPH

DUBLIN, Dec. 9, 2025 /PRNewswire/ -- ProVerum Limited, a medical device company focused on innovative, safe and effective solutions for treating benign prostatic hyperplasia (BPH), today announced it ...